Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer
- 16 October 2026
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-15
Abstract
Perioperative treatment plays an increasingly important role in improving outcomes for patients with resectable non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) offers a new perspective for optimizing individualized perioperative management. This review systematically examines the core value of ctDNA in perioperative therapy for resectable NSCLC, encompassing its correlation with treatment response and pathological remission during the neoadjuvant phase, its utility as a dynamic monitor of treatment efficacy, and its emerging role in prognostic stratification and recurrence prediction in the postoperative setting. Importantly, while ctDNA demonstrates considerable promise for guiding individualized perioperative management, most applications remain investigational; we therefore distinguish between established correlative uses and prospective strategies currently under evaluation in clinical trials. It also addresses current technical challenges in ctDNA application, including limited sensitivity, false positives, lack of standardization, cost-effectiveness concerns, and difficulties in integration into clinical decision-making. Future prospective interventional studies are needed to validate ctDNA-guided treatment adjustments and to establish standardized protocols and multidisciplinary collaboration pathways, thereby facilitating the integration of ctDNA into the full course of perioperative management for NSCLC and enabling precise efficacy assessment, risk stratification, and individualized treatment decisions.Keywords
This publication has 72 references indexed in Scilit:
- Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysisClinical and Translational Oncology, 2025
- The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancerDiscover Oncology, 2025
- Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysisMolecular Diagnosis & Therapy, 2024
- Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung CancerJAMA Oncology, 2024
- Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysisJournal of Cancer Research and Clinical Oncology, 2024
- Management of locally advanced non‐small cell lung cancer: State of the art and future directionsCancer Communications, 2023
- Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLCMolecular Oncology, 2022
- Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patientsMolecular Oncology, 2022
- Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1Molecular Oncology, 2022
- Systemic Therapy for Lung Cancer Brain MetastasesCurrent Treatment Options in Oncology, 2021